Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC)...

March 27, 2020

Markets

HCW cuts aTyr Pharma to neutral and removes PT

H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...

March 27, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Markets

AGP cuts Harvest Health to neutral; PT to $1.60 from $8

Alliance Global Partners downgraded Harvest Health & Recreation (CSE:HARV) to “neutral” from “buy” and slashed its price target to $1.60 (Canadian) from $8 after the company and Verano Holdings mutually agreed to...

March 26, 2020

Markets

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

March 26, 2020

Markets

AGP cuts T2 Biosystems PT to $1.10 from $1.80

Alliance Global Partners lowered its price target for T2 Biosystems (NASDAQ:TTOO) to $1.10 from $1.80 after the company released lower than expected first quarter results but added a COVID-19 program to its platform...

March 26, 2020

Markets

AGP ups OpGen PT to $5 from $2.50

Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $5 from $2.50 after the company reported better than expected fourth quarter results. The stock closed at $2.99 on March 24. OpGen also...

March 25, 2020

Developments

Obalon hires Canaccord Genuity to explore financial and strategic alternatives

The board of Obalon Therapeutics (NASDAQ:OBLN) decided to explore potential financial and strategic alternatives intended to enhance stockholder value and has retained Canaccord Genuity as its financial advisor. The...

March 25, 2020

Markets

Ladenburg ups Novavax PT to $24 from $16

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $24 from $16 after the company reported impressive pivotal results with its lead asset, NanoFlu. The stock closed at $12.77 on March 24. Analyst...

March 25, 2020

Markets

Stifel starts Molecular Templates at buy; PT $19

Stifel initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $19 price target. The stock closed at $13.29 on March 24. “We believe the engineered toxin body technology from which Molecular’s...

March 25, 2020

Markets

Roth starts Immunic at buy; PT $44

Roth Capital Partners launched coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $44 price target. The stock closed at $5.74 on March 24. Immunic is focused on developing innovative new modulators of the immune...

March 25, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...

March 24, 2020

Subscribe